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824Objectives: Fractional flow reserve–guided coronary artery bypass grafting is emerging in cardiac surgery, in
which the nature (anatomic and functional characteristics) of the target vessel epicardial coronary artery stenosis
is important in graft site selection. The nature of the stenosis might determine a different physiologic response to
bypass grafting. We report our recent experience using near infrared fluorescence complex angiography and
perfusion analysis to identify the nature of stenoses in the target vessel by imaging the physiologic response
to grafting.
Methods: In 167 patients who underwent consecutive multivessel coronary artery bypass grafting cases (63%
off-pump coronary artery bypass grafting) with traditional anatomy-based revascularization, we imaged and
analyzed 359 grafts (53% arterial). This platform provides angiographic data of both the target vessel epicardial
coronary artery and graft simultaneously (to assess the imaged competitive flow); and because a change in
fluorescence intensity is proportional to the change in blood flow and perfusion, the quantified change
(if any) in regional myocardial perfusion surrounding the grafted target vessel epicardial coronary artery.
Results: The patient outcomes in our series were excellent. All 359 grafts werewidely patent by angiography, and
24% of the arterial and 22% of the saphenous vein grafts showed no regional myocardial perfusion change in
response to bypass grafting. In 165 in situ internal mammary artery grafts to the left anterior descending artery
(>70% stenosis), 40 had no change in regionalmyocardial perfusion, and 32of the 40had competitive flow imaged.
Conclusions: An important number of angiographically patent bypass grafts demonstrated no change in
regional myocardial perfusion, suggesting anatomic, but nonfunctional, stenoses in those target vessel epicardial
coronary arteries. In in situ arterial grafts, imaged competitive flow is associated with nonfunctional
stenoses in the target vessel epicardial coronary artery. Imaging these physiologic responses to target vessel
revascularization might be useful in the emerging fractional flow reserve–guided era. (J Thorac Cardiovasc
Surg 2013;146:824-35)Video clip is available online.
Supplemental material is available online.e Department of Cardiovascular Sciences, East Carolina Heart Institute,
School of Medicine at East Carolina University, Greenville, NC.
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The Journal of Thoracic and Cardiovascular SurgFor 50 years, the conceptual and practical basis of surgi-
cal revascularization with coronary artery bypass grafting
(CABG) has been the underlying coronary anatomy1 and
the accompanying stenotic2 atherosclerotic plaque and/or
thrombotic occlusion in the target vessel epicardial coro-
nary artery (TVECA). Early on, incomplete revasculariza-
tion within this anatomy-based construct was associated
with a 15% reduction in 5-year survival,3 and the principle
of complete anatomic revascularization became linked to
these anatomic stenotic triggers.
Using this approach, the outcomes from isolated CABG
have improved dramatically, despite the significant increase
in preoperative risk of patients undergoing CABG.4,5 The
5-year results from the Synergy between Percutaneous
Coronary Intervention with Taxus and Cardiac Surgery6
(SYNTAX) and Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Management of
Multivessel Disease7 (FREEDOM) trials, along with obser-
vational database analyses, have documented that in certain
patient populations, CABG is a preferable treatment alter-
native to multivessel percutaneous coronary intervention
(PCI), because a long-term mortality benefit is conveyed
with CABG.8ery c October 2013
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CAPA ¼ complex angiography and
perfusion analysis
COURAGE ¼ Clinical Outcomes Utilizing
Revascularization and Aggressive
Drug Evaluation
CPB ¼ cardiopulmonary bypass
FAME ¼ Fractional Flow Reserve Versus
Angiography for Multivessel
Disease
FFR ¼ fractional flow reserve
FREEDOM ¼ Future Revascularization
Evaluation in Patients with
Diabetes Mellitus: Otpimal
Management of Multivessel
Disease
ICF ¼ image-described competitive flow
ICG ¼ indocyanine green
IDAP ¼ image data acquisition protocol
IDS ¼ image data sequence (34 seconds)
IMA ¼ internal mammary artery
NIRF ¼ near-infrared fluorescence
OPCAB ¼ off-pump CABG
PCI ¼ percutaneous coronary
intervention
PREVENT-IV ¼ Project of Ex-vivo Vein Graft
Engineering via Transfection IV
RA ¼ radial artery
RMP ¼ regional myocardial perfusion
SVG ¼ saphenous vein graft
SYNTAX ¼ Synergy between Percutaneous
Coronary Intervention with Taxus
and Cardiac Surgery
TVECA ¼ target vessel epicardial coronary
artery
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of patients with chronic stable angina in need of revascular-
ization continues. TheClinicalOutcomesUtilizingRevascu-
larization and Aggressive Drug Evaluation9 (COURAGE)
trial established the importance of optimal medical therapy
for these patients, and a substudy identified the requirement
of a significant (>10%) degree of myocardial ischemia for
revascularization strategies to have clinical benefit.10 In a
paradigm shift, fractional flow reserve (FFR) analysis of
anatomic lesions has transformed an anatomic stenosis to a
‘‘functional stenosis’’ classification.11 In such cases, the
anatomic lesion is presumptively linked to regional ischemia
and/or a perfusion deficit in the surrounding myocardium
supplied by the TVECA. In the Fractional Flow Reserve
VersusAngiography forMultivesselDisease (FAME) trial,12The Journal of Thoracic and Ca20% of the anatomic lesions with 71% to 90% stenosis and
60% of lesionswith 51% to 70% had nomeasured function-
ality. In the FAME 2 trial,13 many patients with more severe
3-vessel anatomic disease were reclassified as having 2- or
1-vessel functional disease.
Thus, surgical revascularization is at the point at which
anatomy as the sole criterion for the revascularization
strategy needs to be reconsidered. We report a unique,
real-time intraoperative imaging technology to identify
differences in the physiologic (angiographic and functional)
response to revascularization, on a per graft basis. These
physiologic findings could be critically important in a
FFR-guided revascularization strategy adapted for CABG.METHODS
Imaging Technology Developments
Near-infrared fluorescence (NIRF) angiography in CABG has been
previously described, with mixed results.14-18 The fidelity of NIRF
versus conventional angiography was inferior, but the technique was
better at identifying potential anastomotic technical issues than transit-
time flowmetry.19
NIRF uses the nontoxic fluorophore indocyanine green (ICG) dye,
administered as a bolus injection into the blood stream.20,21 The
pharmacokinetics of its binding to endothelial cells and circulating
proteins, its metabolism by the liver, and excretion by the kidneys is
well-understood, with a half-time of approximately 90 seconds. The
fluorophore is excited by a low-energy NIR laser, and the fluorescence image
data are collected as a 34-second image data sequence (IDS) of 1020 images
at a camera speed of 30 frames/s. Because no radiation is involved, this full
34-second image data set can be safely captured with each ICG injection.
ICG fluorescence behavior in the heart has been studied in nearly 1000
patients, and we have confirmed clinically the experimental data validating
that the ICG behavior is consistent on the first pass through the coronary
arteries; the fluorescence intensity is proportional to the concentration of
dye and dose administered and to the circulating blood volume; and under
certain conditions, the regional fluorescence intensity is directly proportional
to themyocardial bloodflowandmyocardial perfusion.22Therefore, a change
in fluorescence intensity will be a direct indicator of a corresponding change
in myocardial perfusion.
Early on, we recognized that the 34-second image data sequence
contained considerably more information about the myocardial blood
flow and perfusion than did angiography alone. We developed, tested,
and implemented a complex angiography and perfusion analysis (CAPA)
platform into the NIRF system for real-time intraoperative analysis.
Clinical Experience With NIRF-CAPA
From May 2009 (when the image data acquisition protocol [IDAP] for
the post- versus pregrafting comparison with the CAPA platform was
validated) through March 2013 (to allow for full 30-day follow-up), we
performed 167 consecutive isolated CABG procedures with 2 grafts
placed. All patients underwent CABG by 1 of us (T.B.F., Jr), using
predetermined revascularization strategy-based anatomy, with a revascu-
larization trigger of 70% for TVECAs and>50% for left main disease.
We attempted to image all the grafts in all patients using this standardized
IDAPand platform.Technical reasonswere the cause for nonimagedpatients
and/or grafts; this diminished with accrued experience. All patient clinical
characteristics were captured in a combined American College of Cardiol-
ogy/Society of Thoracic Surgeons clinical database for analysis.
The raw IDS and the NIRF-CAPA analysis data were stored in a unique
data construct that directly combined the imaging data with the clinical
data; thus, access to the raw imaging data files was always available forrdiovascular Surgery c Volume 146, Number 4 825
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image analysis algorithms over time during their development.
Statistical Analysis
The institutional review board at East Carolina University approved the
present longitudinal study.
The clinical data are expressed as continuous or discrete variables
as mean values and percentages. The Society of Thoracic Surgeons
benchmarks from the latest available analysis (quarter 3, 2012) were
used for comparison of the clinical demographics and outcomes.
Histogram plots were assessed by comparing the slope of the log exponen-
tial decay curves. P<.05 was considered significant.
RESULTS
Clinical Data Set
The clinical population demographics, procedural char-
acteristics, and outcomes of the patients undergoing
revascularization (Table 1) were consistent with those
of contemporary surgical revascularization populations re-
ported recently.5,23
The results for these patients were, in general, better than
the national benchmarks. Also, the consistent use of the
NIRF-CAPA platform did not create any unforeseen
complications or adverse effects in our population.
NIRF Imaging and CAPA Platform
Figure 1, A, is a single frame from the IDS, highlighting
the angiographic characteristics of the TVECA and graft.
Video 1 illustrates the entire 34-second IDS of this in
situ left internal mammary artery (IMA) to left anterior
descending coronary artery graft. The NIR spectrum is
beyond the visible wavelengths; thus, the standard image
presentation is a 1 to 255 gray scale image.
We adapted and developed several color presentation
schemes to illustrate intuitively the image data presentation.
Application of these schemes did not alter the underlying im-
agemetadata or require image processing. Figure 1,B, shows
the same graft at peak fluorescence, highlighting the perfu-
sion to the surrounding myocardium. This is presented
dynamically from this perfusion perspective in Video 2.
Figure 2 illustrates the CAPA platform analysis presenta-
tion construct and representative NIRF-CAPA analyses.
Both the pre- and postgrafting image sequences, acquired
some 30 seconds apart, were incorporated into the CAPA
platform presentation. The IDAP is designed such that, if
properly executed, the hemodynamic, coronary autoregula-
tion, pharmacologic, and image data acquisition influences
on the IDS metadata will be controlled and therefore will
not influence the relative comparison analysis.
Figure 2 presents the analysis from2 different patients un-
dergoing in situ IMA grafting to the left anterior descending
coronary artery. Both TVECAs had 75% proximal stenoses,
as assessed preoperatively. Using NIRF angiography, both
grafts were widely patent, with no technical issues identi-
fied. However, a significant increase occurred in regional
myocardial perfusion (RMP) as a result of bypass grafting826 The Journal of Thoracic and Cardiovascular Surgin the patient whose data is shown in Figure 2, A, but no in-
crease was seen in RMP in the patient with data shown in
Figure 2, B. Using this NIRF-CAPA platform on a per graft
basis, we examined the relative occurrence of RMP changes
and the possible causes of these differences.
Clinical and Imaging Data Set
A total of 167 patients underwent isolated CABG (67%
urgent), with 2 grafts (Figure 3). Of these patients, 7
were eliminated because technical reasons obviated a
quantitative comparison.Of the 160 patients, 105 underwent
standard off-pump CABG (OPCAB), and 55 underwent
conventional on-pump CABG with cardioplegic arrest
(14%), or, more recently, beating heart CABG with cardio-
pulmonary bypass (CPB) support at near normothermia. In
the CPB patients, imaging was performed for each graft
during CPB, with stable hemodynamics and some ejection
to effect normal pulsatile coronary perfusion, either after
each graft or before weaning from CPB. During OPCAB,
imagingwas performed immediately after graft construction
per the IDAP.
A total of 386 grafts were imaged in these 160 patients.
The total number of grafts constructed in this group was
434 (2.7 grafts/patient); the difference was that grafts to
the back of the heart in cardioplegic arrest cases were not
imaging early in our experience. From these 386 imaged
grafts, 359 could be analyzed using the CAPA platform.
The technical problem with the 27 nonanalyzed grafts
was usually related to ICG injection in the patients on
CPB; since changing this component of the IDAP, this
problem has been eliminated.
Of the 359 analyzed grafts, 192 (53.4%) were arterial,
and 167 (47%) were saphenous vein grafts (SVGs)
(Figure 3). Of the arterial grafts, 165 were in situ IMA grafts
and 27 were radial artery (RA) grafts.
All 359 grafts were documented in the NIRF angio-
graphic evaluation on a per-graft basis to be widely patent;
however, only 275 of the grafts (77%) had at least a
minimum 5% to 10% increase in RMP documented
(Figure 3, A). The remaining 84 grafts (23%) had no
quantified increase in RMP.
In the subset of patent arterial grafts without an RMP
increase (Figure 3, B), we identified specific angiographic
characteristics that were then correlated with the ‘‘imaged
competitive flow (ICF).’’ Video 3 illustrates the character-
istic findings of ICF in an in situ arterial graft in which no
RMP increase occurred.
Figure E1 shows a histogram plot of the relative
frequencies of RMP increase, by graft category, for all
359 grafts in the 160 patients. These histogram frequency
plots were curve fitted with exponential decay curves for
comparison between in situ IMA and aortocoronary
(SVG/RA) grafts. Comparing the log exponential decay
curves, the curve for the IMA group had a longer andery c October 2013
TABLE 1. Patient characteristics (n ¼ 167)
Variable
Patients
(n)
STS Q3 2012
Benchmark (%)
Demographics
Age 65 yrs 106 (63.5) 53.3
Gender
Male 122 (73.1)
Female 45 (27.0) 25.9
BMI 30 kg/m2 71 (42.5)
Active smoker 56 (33.5) 33.4
Hypertension 150 (89.8) 87.3
Dyslipidemia 152 (91.0) 86.4
Diabetes mellitus 78 (46.5) 44.6
Cerebrovascular disease 27 (16.2) 14.3
Previous CVA 16 (9.6) 7.2
RF, preoperative dialysis 10 (6.0) 2.7
Coronary anatomy
1-Vessel CAD 5 (3.0) 4.4
2-Vessel CAD 40 (24.0) 19.9
3-Vessel CAD 122 (73.1) 75.3
LM 50% 44 (26.4) 33.0
Myocardial function
EF<40% 30 (18.0) 15.5
NYHA class III 26 (15.6)
NYHA class III 13 (7.8) 6.0
NYHA class IV 13 (7.8) 3.9
Previous PCI 39 (23.4) 28.6
History of MI 112 (67.1) 50.5
Operative data
IMA used 159 (95.2) 95.0
>1 distal arterial graft 57 (34.1)
Perioperative MI 1 (0.6)
On-pump 62 (37.1)
Beating heart 38 (22.8)
Cardioplegic arrest 24 (14.3)
OPCAB 105 (62.8) 18.0
Status
Elective 52 (31.1) 39.0
Urgent 112 (67.1) 56.1
Emergent or salvage 3 (1.8) 4.6
Outcomes
PROM 1.9%
O/E
Mortality or morbidity [0.72] 1.0
Mortality [0.64] 1.0
Reoperation [0.58] 1.0
Permanent stroke [0.47] 1.0
RF [0.00] 1.0
Prolonged ventilation [0.76] 1.0
Short length of stay [1.16] 1.0
Long length of stay [0.76] 1.0
Data in parentheses are percentages; data in brackets are O/E ratios. STS, Society of
Thoracic Surgeons; BMI, body mass index; CVA, cerebrovascular accident; RF, renal
failure; CAD, coronary artery disease; LM, left main (artery); EF, ejection fraction;
NYHA, New York Heart Association; PCI, percutaneous coronary intervention;
MI, myocardial infarction; IMA, internal mammary artery; OPCAB, off-pump
coronary artery bypass grafting; PROM, predicted risk of mortality; O/E, observed/
expected ratio.
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The Journal of Thoracic and Cabroader decay than the SVG/RA grafts, reflecting a physio-
logic difference between the graft conduits and the TVECA.
Figure 4 shows a 2-dimensional representation of the
physiology of multivessel revascularization from 2 different
patients undergoing OPCAB. In both cases, an anatomic
strategy for revascularization was used, all 3 bypassed
TVECAs had a minimum of 70% proximal stenoses,
and all grafts were widely patent using NIRF. The RMP
change was compared with the baseline pregraft status
(Figure 4, white). Patient 1 had a minimal increase in the
anterior and lateral perfusion areas, with a substantial
twofold increase in the inferior right coronary artery
distribution (Figure 4, yellow). In sharp contrast, patient 2
had substantial increases in RMP in all 3 (1.45-fold anterior,
1.6-fold inferior, and 2.8-fold lateral) regions of the heart as
a result of CABG.A
C
DDISCUSSION
Influences beyond the coronary anatomy alone can
affect the physiologic consequences of CABG, as we have
demonstrated in our study for the first time.
These NIRF-CAPA platform data have demonstrated (1)
consistent findings in both in situ arterial and aortocoronary
arterial and vein grafts, from a representative patient
experience; (2) analysis on a per graft basis; (3) how the
use of standardized intraoperative imaging technology can
open a critical new window into the real-time physiologic
assessment of surgical revascularization; and (4) how this
use can contribute to a more complete understanding of
the factors that constitute reasonable incomplete revascular-
ization24 at CABG.
By collating both the angiographic and the functional
consequences of revascularization, unique clinical physio-
logic data are now available that challenge important
CABG assumptions, including the anatomic construct for
the CABG intervention strategy, competitive flow, and graft
patency.
By illustrating in a new and fundamental way the physi-
ology of revascularization, this NIRF-CAPA platform
creates the opportunity for CABG to move in parallel
with the recent physiology-based developments in FFR-
directed PCI. Whether FFR-guided CABG25-27 will realize
the same improved outcomes is a critical question for
surgeons, especially because of the now well-documented
long-term mortality benefit of CABG for patients with
severe multivessel coronary artery disease.NIRF-CAPA Platform
The NIRF-CAPA platform uniquely generates, from a
single video sequence, both angiographic and functional
evaluation of grafts to TVECAs. Because CABG is
intended to improve myocardial perfusion, feedback onrdiovascular Surgery c Volume 146, Number 4 827
FIGURE 1. Physiologic imaging of angiography and perfusion with near-infrared fluorescence complex angiography and perfusion analysis. A, A single
frame at near-peak fluorescence from the 1020 frames captured in each 34-second video sequence with near-infrared fluorescence angiography of an in situ
internal mammary artery to the left anterior coronary artery graft. The raw data are presented as a 1 to 255 grey scale because the near-infrared spectrum is
outside the visible spectrum. This grey scale best illustrates the angiographic component of the dynamic image data. B, The same single frame at near-peak
fluorescence. These data are presented to highlight perfusion rather than angiography. This color scheme presents alternative warm and cold colors to
facilitate the visual differentiation between levels of fluorescence, which represent differences in levels of perfusion. Note that no manipulation of the
raw image metadata is required to generate these displays.
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perfusion is important to assess the full benefit of the
surgical revascularization.
NIRF technology was approved by the Food and Drug
Administration for use in cardiac surgery in 2005, with
CAPA platform development occurring during the previous
6 years. This has included the careful evaluation of a
number of intraoperative, hemodynamic, physiologic,
pharmacologic, and metabolic factors that could influence
the imaging analysis results.
The critical importance of the IDAPwas validated by beta
testing of the CAPA software at centers worldwide. Because
themeasurement of perfusion is dependent on the conditions
at measurement, the NIRF-CAPA IDAP (90 to 100 s/graft)
generates a relative post- to pregraft comparison in which
the differences in conditions that could affect perfusion
and the measured change are minimal. This approach was
readily adaptable to both on-pump and off-pump per graft
analyses. Because bypass grafting augments blood flow to
the TVECAmyocardium if the myocardium can physiolog-
ically respond to the additional blood flow, when a change in
perfusion is identified, it will reflect resolution from a
deficiency status. Our study results have indicated that using
the anatomic criteria, 75% to 80% of grafts will provide this
resolution,whichmight be the intraoperative documentation
of the relief of the preoperative ischemia or perfusion deficit
seen with FFR. The per graft analysis metadata can be
aggregated to illustrate the global physiologic effect of
surgical revascularization compared with the preoperative,
TVECA perfusion baseline (Figure 4).
Per Graft Imaging and Analysis
The present study’s findings address, with this real-time
physiologic data and analysis, 3 assumptions about bypass
grafts to TVECAs that have developed over the years.
The nature of stenoses in TVECAs. The first assumption
is that the anatomic stenosis is the only preoperative consider-
ation important in surgical revascularizationdecision-making.828 The Journal of Thoracic and Cardiovascular SurgHowever, a failure to increase RMP in angiographically
patent grafts (24% arterial, 22% SVGs) suggests nonfunc-
tionality of the TVECA stenosis compared with the a
priori expectation that all grafts will improve blood flow
and perfusion. This incidence was similar to the 20%
occurrence of nonfunctionality seen in lesions with
angiographic anatomic stenoses between 71% and 90%
in FAME 1.12
In an early prospective study applying FFR to pre-CABG
patients, Botman et al28 correlated the 1-year graft patency to
the corresponding stenosis functionality. Revascularization
was determined using the traditional anatomic strategy, and
the surgeon was unaware of the preoperative FFR results.
At 1 year, 8.9% of the bypass grafts to functional TVECAs
were occluded, and 21.4% of the grafts to nonfunctional
stenoses were occluded. On retrospective comparison, 168
of the 525 grafts (32%) were to TVECAswith nonfunctional
stenoses by FFR. This percentage was slightly greater than
the incidence of negative RMP change in the present study
(22% to 24%). However, in the study by Botman et al,28
the cutoff of significance for FFRwas0.75, and intermedi-
ate anatomic lesions (50% to 70% stenosis) were grafted.
Finally, the similarity of the RMP percentage of change
in both in situ IMA and aortocoronary grafts in Figure 3
suggests a common underlying influence in both graft
categories, namely the nature of the TVECA stenosis.
These data, in aggregate, support the consideration that
the nature of the TVECA stenosis in CABG is important.
Imaged competitive flow. A second assumption relates to
the competitive flow between the TVECA and the graft
conduit. Anatomic proximal lesion stenosis has been the
surrogate for competitive flow in most studies,29,30 but the
findings from the present study suggest other influences
are important.
One important angiographic advantage of this platform
compared with all other evaluation technologies is that
both the native TVECA and the bypass conduit can be
imaged at the same time, under physiologic conditions.ery c October 2013
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interaction between the 2 conduits in real time.
The subset of in situ IMA grafts without an increase in
RMP helped determine the importance of the ICF in such
circumstances. In in situ IMA grafts, the association
between no change in RMP and ICF was high (80%).
Of the 165 IMA grafts, 42 had evidence of ICF on the
NIRF-CAPA angiographic evaluation, and 94% of these
ICF grafts had no change in RMP.
This opportunity to characterize ICF both angiographic-
ally and functionally (Video 3) will substantially facilitate
better understanding of the effects of ICF on the flow
dynamics and graft patency. These in situ arterial graft
findings are additional evidence that the functionality of
the proximal stenosis at CABG might be as important as
suggested by the FAME studies. Clearly, the etiology and
significance of ‘‘competitive flow’’ is more complex than
the percentage of anatomic stenosis alone and must also
account for the functionality of the stenosis.
In contrast, as shown in Figure 3, ICF has not been
identified in SVGs and in only 1 RA graft, thus far.
Additional investigation is ongoing, and the difference
might be related to the conduit size and the hemodynamics
of aortocoronary blood flow versus native epicardial
coronary flow versus in situ IMA flow.
This constellation of angiographic patency, no ICF, and
no increase in RMP for ‘‘unknown reasons’’ occurred
more frequently in the aortocoronary conduits than in the
in situ IMA conduits. The data shown in Figure E1 suggest
a subtle, but significant, difference between these 2 conduit
types, in which an increase in RMP occurs. These data
highlight that an assumption that bypass grafting beyond
‘‘critical stenoses’’ provides a physiologic improvement
to the patient’s heart, as measured at surgery, is not always
correct.
Imaging, functionality, and graft failure in CABG. The
present study has also provided new information about
possible causes of intermediate graft failure. Bypass grafts
beyond anatomic stenoses should not affect ischemia or
perfusion deficits; grafts beyond functional stenoses should
provide physiologic relief of both these circumstances.
In the study by Botman et al,28 the patency rates were signi-
ficantly greater in the functional intermediate (anatomic
stenoses 50% to 70%) lesions bypassed; however, no
difference was found in the angina class between patients
with occluded versus patent grafts. This absence of clinical
consequences from graft occlusion is similar to the findings
from the Project of Ex-vivo Vein Graft Engineering via
Transfection IV (PREVENT IV) study,31 in which, overall,
26% of the SVGs were occluded at protocol-specified
angiography. However, the 1-year angiographic occlusion
did not predict an increase in mortality or death compared
with patients without graft occlusion at 5 years.32 In brief,
in both studies, the grafts might have been occluded simplyThe Journal of Thoracic and Cabecause no TVECA regional physiologic drive was present
to keep the graft open. This would be the case if the
occluded grafts were placed to TVECAs with anatomic,
but not functional, stenoses.
In chronic stable ischemia, the relief of a significant
(>10%) amount of ischemia is the functional component
of reasonable incomplete revascularization, as described
by Dauerman24 and others.33,34 Additional studies will
determine whether the NIRF-CAPA finding of increased
RMP is the intraoperative correlate of the relief of signifi-
cant ischemia or the relief of (and thereby evidence of) a
regional myocardial perfusion deficit by FFR. Our data
thus far have seemed to suggest that this might be the
case, based on the distribution and nature of the bypassed
stenoses in the present study. Our data have further
suggested that the physiologic status of the myocardium
might play a significantly important role in graft attrition.
Imaging and FFR-Guided CABG
In an FFR-guided CABG construct, TVECAs with
documented functional stenoses would be bypassed. In
addition, most believe that surgeons would need to bypass
nonfunctional, but anatomic, stenoses (ie,>70% proximal
left anterior descending coronary artery stenoses) deemed
important based on historical information or for acute
surgical indications. If the consequence of this FFR-
guided strategy is to decrease the number of grafts
performed, it would challenge the principle of complete
anatomic revascularization but perhaps adds to a better
understanding of reasonable incomplete revascularization.
However, at this point, the effect of these nonfunctional
stenoses in PCI revascularization is much better under-
stood than in CABG. Although we can hypothesize what
might be the fate of grafts to anatomic but nonfunctional
stenoses, we do not know for sure whether the conse-
quence will be adverse (failure leading to myocardial
infarction and poorer long-term survival) or beneficial
(‘‘protective’’ effect as long as the graft is open, contrib-
uting to the long-term mortality benefit versus PCI in
the SYNTAX and FREEDOM trials). The use of
intraoperative imaging to physiologically document the
nature of the TVECA stenoses would help connect the
preoperative data with short- and long-term outcome
data, on a per graft basis.
Study Limitations
The present study had several important limitations.
First, we have reported a single-center experience with
the NIRF-CAPA imaging technology from the center that
developed the CAPA platform. These findings must be
replicated for additional validation of the analysis results.
However, the consistency and scope of the present study
suggest that these imaging results accurately reflect the
underlying physiology of surgical revascularization.rdiovascular Surgery c Volume 146, Number 4 829
FIGURE 2. The complex angiography and perfusion analysis platform presentation construct, with representative patient analyses. Dynamic video and
relative perfusion comparisons are displayed. Unique synchronization of the postgrafting (lower right) versus pregrafting (lower left) image sequences
allowed for nonquantitative, but visual, comparison of these data. The complex angiography and perfusion analysis platform analyzes the underlying video
metadata for the quantitative comparison of the postgrafting versus pregrafting regional myocardial perfusion in the regional territory supplied (at least in
part) by the grafted target vessel epicardial coronary artery. This relative comparison is presented using 2 methods in this scheme.Upper right, The blue line
represents perfusion before grafting, with only the native target vessel epicardial coronary artery supplying the myocardial region; the red line represents
perfusion after grafting, with both the target vessel epicardial coronary artery and graft supplying the myocardial region; and the green line is the calculated
difference in myocardial perfusion, if any, as a result of bypass grafting. Upper middle, The bar graph normalizes the pregraft perfusion to 1 and illustrates
this relative comparison as a ratio against this normalized value. A and B, Analysis from 2 different patients undergoing in situ internal mammary artery
grafting to the left anterior descending coronary artery. A, A significant increase occurred in regional myocardial perfusion in the anterior wall.
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FIGURE 3. Diagram illustrating the clinical and imaging flow of the study. CABG, Coronary artery bypass grafting; OPCAB, off-pump CABG; ICF,
image-described competitive flow; IMA, internal mammary artery; RA, radial artery; SVG, saphenous vein graft; RMP, regional myocardial perfusion, as
assessed using near-infrared fluorescence complex angiography and perfusion analysis.
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RMP and documented perfusion deficits and regional
ischemia preoperatively in these patients. This correlation
would confirm that the change in RMP with grafting
was a physiologic response to that perfusion deficit or
ischemia. Several studies, including the FAME 3 study
and the National Heart, Lung, and Blood Institute
Cardiac Surgical Network FFR-CABG Trial, are being
designed to specifically leverage this preoperative func-
tional anatomy with functional outcomes. IntraoperativeB, No increase occurred in regional myocardial perfusion, despite widely pa
fluorescence complex angiography and perfusion analysis evaluation. The patien
ding coronary artery fractional flow reserve of 0.73, and the patient whose data
The Journal of Thoracic and Cadocumentation of the physiologic consequences of revascu-
larization on a per graft basis might be useful in these
circumstances.
Third, the present clinical experience was mostly accrued
from patients undergoing either OPCAB or beating heart
CABG with CPB support. Although this created the enor-
mous opportunity to study revascularization physiology
in real time, additional study is necessary to determine
whether these beating heart results can be demonstrated
after CABG with cardioplegic arrest.tent bypass grafts beyond 75% stenoses according to the near-infrared
t whose data are shown in Figure A had a preoperative left anterior descen-
are shown in part B had a preoperative fractional flow reserve of 0.81.
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FIGURE4. The individual regional myocardial perfusion data for 2 patients who had undergonemultivessel off-pump coronary artery bypass graftingwere
aggregated into a 2-dimensional representation of the global change in perfusion in the heart as a result of bypass grafting. In case 1, only the inferior wall
region had an increase in myocardial perfusion with grafting. In case 2, however, a significant change in perfusion occurred in all 3 areas as a result of
revascularization. In both cases, all grafts were widely angiographically patent as documented by the near-infrared fluorescence angiographic evaluation.
The difference between these 2 patients’ physiologic outcomes with bypass grafting highlight the importance of a new knowledge opportunity inherent in
intraoperative physiologic evaluation of both angiography and perfusion at bypass grafting. CX, Circumflex region; LAD, left anterior descending region;
LIMA-LAD, left internal mammary artery to left anterior descending; RCA, right coronary artery region; RA-PDA, right coronary-posterior descending
artery; SVG-CX, saphenous vein graft to circumflex marginal; SVG-RCA, saphenous vein graft to right coronary artery.
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limitation and opportunity. The experience accrued from
imaging almost 1000 patients and some 3000 grafts with
NIRF-CAPA has confirmed that a better understanding
of the physiology of surgical revascularization requires
sophisticated intraoperative technologies that can directly
link imaging to the underlying physiology. At present, the
most comprehensive representation of the angiographic
and functional consequences of surgical revascularization
on a per-graft based is with the NIRF-CAPA platform
technology we used in the present study.
CONCLUSIONS
We have presented the initial experience documenting
that the nature of the TVECA stenosis is important in
determining the imaging-based physiologic consequences
of CABG, on a per graft basis. The information imbedded
in real-time intraoperative imaging at CABG promises to832 The Journal of Thoracic and Cardiovascular Surgimprove the physiologic understanding and outcomes of
surgical revascularization in the FFR era.References
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Dr Joseph F. Sabik (Cleveland, Ohio). I would like to congrat-
ulate Dr Ferguson and colleagues on a fine presentation and study
and thank them for providing me with a copy of their report in
advance of the meeting.
As we heard, the authors used NIRF-CAPA to evaluate the
functional importance of coronary artery stenosis by comparing
myocardial perfusion before and after CABG. They found that
despite significant coronary artery stenosis by angiography, bypass
grafting did not improve myocardial perfusion in slightly>20% of
the territories grafted, suggesting to the authors that these stenoses
were not functionally significant and therefore did not need
grafting and that grafting them might have led to harm. I have a
few questions for the authors.
My first question has to dowith the usefulness of this technique.
Whether coronary artery stenosis is physiologically significant is
important to know before grafting. With this technique, the
functional significance of the stenosis is determined only after
the artery has been grafted. How can this technique guide in
decision-making as the title of your presentation suggests?
My second question has to do with whether measuring changes
in myocardial perfusion without stress is an accurate method of
determining the functional significance of a coronary blockage.
The physiologic test used to determine the functional importance
of coronary artery stenosis is to provoke the myocardium with
stress. For instance, during the measurement of a functionally
significant coronary stenosis using FFR, a vasodilator, such as
adenosine, is given to induce hyperemia before measuring the
decrease in perfusion across the stenosis. In your measurement
of myocardial perfusion, no stressing of the myocardium has
been done either before or after grafting. For example, for the
procedures done on pump, the blood flow measurements were
made with the patient still on cardiopulmonary bypass, a very
low workload on the myocardium. Is it not possible that this
method might have underestimated the functional significance of
the coronary stenosis?
My third question is, because of studies such as FAME 1
and FAME 2, the importance of not stenting nonphysiologicrdiovascular Surgery c Volume 146, Number 4 833
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your report, you extrapolated these findings to also apply to
coronary artery bypass grafting. These 2 revascularization
techniques are very different, and one could hypothesize that
grafting a nonphysiologic stenosis might result in only the graft
closing, with no resultant harm to the patient. In your report, you
showed excellent results for the entire group of patients. Did
you compare the outcomes in the patients with grafts that did
not increase myocardial perfusion with those with grafts that
did increase myocardial perfusion, and if you did, were there
any differences?
My final question has to do with the FFR data that were
collected preoperatively for some patients. Were you able to
determine whether the FFR data you had correlated with your
findings of myocardial perfusion after grafting?
I would once again like to congratulate the authors for an
interesting study and thank the Association for the opportunity
of discussing this report.
Dr Ferguson. Thank you, Dr Sabik, and thank you for your
comments.
After 50 years, the anatomic basis for CABG is changing. We
are moving to an era in which the functionality of target vessel
coronary artery stenoses are going to be characterized in the
catheterization laboratory before patients come to surgery. In
fact, we are going to be faced with a situation in which the
cardiologists tell us to graft this stenosis based on functionality
but do not graft this stenosis based on nonfunctionality. FFR
introduces physiology into the catheterization laboratory, and we
need a method in the operating room to be able to evaluate the
physiologic response to revascularization and to validate the
preoperative results to be able to determine that a patient has
received the full benefit of this operation. This physiologic
evolution certainly seems to be the trend and was the genesis for
the National Heart, Lung, Blood Institute Cardiac Surgical
Network FFR-guided CABG trial that is under discussion and
other trials such as FAME 3 that are under discussion.
With regard to your second question, this is definitely not a
stress evaluation of the myocardium, unlike FFR. This evaluation
is done during a 90-second period in which the heart rate, blood
pressure, and coronary autoregulation are stable to obtain both
the pregrafting image and the postgrafting image.We spent several
years developing and validating that this is the case. Thus, what
you see is a direct comparison, which is the difference in flow
down the epicardial coronary versus the epicardial coronary plus
the graft, and the consequent effect on myocardial perfusion.
Currently, the only correlation with the maximal vasodilation
circumstance with FFR is that 23% of these imaged grafts do
not show a regional myocardial perfusion increase, 20% of the
anatomic lesions between 71% and 90% in FAME did not have
functionality associated with them, and 20% to 25% of the grafts
that we sew have been occluded silently at 1 year, as determined
by protocol-driven angiography in most of our major studies.
As to your third question, we do not yet have formal long-term
follow-up on the fate of the grafts without an increase in perfusion.
In these multivessel CABG patients, however, essentially all
patients in the group had some measured increase in regional
perfusion. At the other end of the spectrum, the number of patients
with a substantial increase in all regions was relatively small,834 The Journal of Thoracic and Cardiovascular Surgapproximately 15% to 20%. The short-term outcomes were
excellent, and the absence of a perfusion increase on a per graft
basis was not associated with acute perioperative events based
on the present analysis.
Addressing your fourth question, we do have data, not yet
published, considering the correlation of the regional myocardial
perfusion change, anatomy, and myocardial ischemia. When
perfusion change is compared with the SYNTAX-characterized
anatomy alone, the correlation was not statistically significant.
If one adds the functionality of the myocardium, from the
FFR, preoperative magnetic resonance imaging level, or clinical
status, that relationship becomes highly significant, suggest-
ing that the measurement of regional myocardial perfusion
change at surgery is an index of the relief of ischemia or the
relief of the perfusion deficit measured preoperatively in these
patients.
Dr Sabik. I would just like to add a word of caution about
FFR-guided surgical revascularization. Some studies have now
shown that if one grafts a vessel that has an FFR>8, only 1 of 5
of those grafts are going to close; 8 of the 10, or 80%, are going
to remain open; and we know that the vessels that cause myocar-
dial infarction are those moderate lesions that thrombose. When
we consider surgery, we are thinking about a long-term solution
to a problem, and those 80% of grafts might very well be protective
over the long run. Also, whenwe think about FFR and stenting, it is
really owing to the periprocedural complications and the restenosis
why stenting does not work. Finally, I just worry that if we
extrapolate the findings of FAME to surgery, we might be doing
80% of our patients harm.
Dr Ferguson. I actually completely agree with you, Joe. This
study is not advocating adopting an FFR-guided strategy for
revascularization. It is advocating imaging of the physiologic
consequences of revascularization in the operating room to learn
how we can improve CABG from a physiologic perspective,
beyond using the anatomy alone.
For example, the late mortality from FREEDOM and SYNTAX
cannot be explained by the anatomy, because both arms of the
intervention in both of those trials were anatomically based.
Thus, something else besides anatomy must be driving the long-
term survival benefit in those patients. Our data suggest that it
might be the functional response to bypass surgery that we have
been creating all along. Understanding the cause of this benefit
will be important in the evolving, physiologic-based revasculariza-
tion era beyond anatomy alone.
Dr John H. Calhoon (San Antonio, Tex). Elegant study. To
continue with what Dr Sabik said, how are you going to use this
technique to help us know how to do CABG or more appropriate
CABG when we are considering the 10-year survival for the
operating room as opposed to the 10-minute outcome in the
catheterization laboratory? I am afraid that this technology falls
into the same category that Joe described, we are considering
use of a technology designed to help cardiologists know when to
intervene on a lesion rather than to help us know what to do for
a patient long term. In other words, how might this technology
be applied successfully in CABG?
Dr Ferguson. The newwindow here is a window of opportunity
into the physiology of revascularization that we accomplish in the
operating room.ery c October 2013
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flow in bypass grafts is potentially a very real asset in our
ability to learn what the influence of competitive flow on
long-term graft survival actually is, because right now we do
not know.
Using the traditional anatomic construct for CABG, we do a
number of tasks based on assumptions but not real data, because
we have never measured it in the operating room.The Journal of Thoracic and CaAs I stated, the idea that something other than anatomy is what
drives the long-term survival from SYNTAX and FREEDOM
trials might be directly linked to what we create functionally at
surgery, which is a safety net of perfusion. Linking the preopera-
tive functional anatomy and long-term outcomes will greatly be
facilitated by the intraoperative assessment of the physiologic
consequences of revascularization, which could be the physiologic
substrate for long-term survival benefit in CABG.rdiovascular Surgery c Volume 146, Number 4 835
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FIGURE E1. Histogram plot of the percentage of grafts with a categorized magnitude of change in regional myocardial perfusion (RMP) as a result of
bypass grafting. Black bars indicate in situ internal mammary artery (IMA) grafts; hashed bars, aortocoronary (saphenous vein graft [SVG]/radial artery
[RA]) grafts. The straight lines represent the log exponential decay curves for the IMA (solid black line) and aortocoronary grafts (dashed line). The slopes
of the 2 lines differed by 25% (P<.05). More clustering of smaller increases (10% to 75%,<2.0) was found in the aortocoronary grafts, and the IMA grafts
(92% to the left anterior descending coronary artery) had a broader range of RMP increases.
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